Related Experiment Video

Updated: Aug 9, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Antisense p53 oligonucleotides inhibit proliferation and induce chemosensitivity in follicular thyroid cancer cells

I Hassan1, A Wunderlich, A Burchert

  • 1Department of Visceral-, Thoracic- and Vascular Surgery, Philipps-University of Marburg, Germany. hassan@med.uni-marburg.de

Anticancer Research
|April 20, 2006
PubMed
Abstract

Insights

Oligodesoxyribonucleotide phosphothioates (ODNs) targeting mutant p53 (MTp53) inhibited proliferation in undifferentiated thyroid cancer (UTC) cells. This MTp53 knockout also enhanced chemosensitivity to Cytarabine treatment.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Genetics

Background:

  • Undifferentiated thyroid cancer (UTC) cells with a recessive MTp53 mutation were studied.
  • The potential of MTp53 knockout using oligodesoxyribonucleotide phosphothioates (ODNs) was evaluated.
  • Effects on proliferation, apoptosis, and chemosensitivity were assessed.

Purpose of the Study:

  • To evaluate the impact of MTp53 knockout on UTC cell behavior.
  • To determine if ODNs targeting MTp53 can inhibit proliferation.
  • To assess the effect of MTp53 knockout on chemosensitivity to Cytarabine.

Main Methods:

  • Transient transfections with p53-complementary ODNs and control ODN (HIV-RT) in FTC 133 cells.
  • In vitro proliferation assessed by cell counting and MTT assay.
  • Chemosensitivity evaluated by flow cytometry after Cytarabine treatment.

Main Results:

  • ODN transfection decreased UTC cell number by up to 70% and proliferation by up to 35%.
  • MTp53 knockout did not induce apoptosis but sensitized cells to Cytarabine.
  • ODNs increased Cytarabine-induced apoptosis to 35% compared to controls (17% and <10%).

Conclusions:

  • Transient MTp53 knockout using ODNs inhibits proliferation in FTC133 cells.
  • ODN-mediated MTp53 knockout enhances chemosensitivity in UTC cell lines.
  • This approach shows potential for treating thyroid cancer with MTp53 mutations.

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...